GLX Analytix, an Aarhus University spinout, envisions a world where early diagnosis and self-monitoring lead to optimized treatments. They aim to revolutionize patient care globally with their AI-enhanced biomarker, the GLX Signature, predicting disease attacks and improving treatment outcomes.
Established in 2018.
